title: Bilateral macular ischemia and severe visual loss following trastuzumab therapy.
authors.forename: Maher
authors.initials: M
authors.lastname: Saleh
authors.forename: Tristan
authors.initials: T
authors.lastname: Bourcier
authors.forename: Georges
authors.initials: G
authors.lastname: Noel
authors.forename: Claude
authors.initials: C
authors.lastname: Speeg-Schatz
authors.forename: David
authors.initials: D
authors.lastname: Gaucher
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology; D005128:Eye Diseases / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D005260:Female; D006801:Humans; D007511:Ischemia / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D008268:Macular Degeneration / Q000139:chemically induced / Q000150:complications; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012720:Severity of Illness Index; D000068878:Trastuzumab; D015354:Vision, Low / Q000139:chemically induced* / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab